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Abstract
Risk factors often develop at young age and are maintained over time, but it is not fully
understood how risk factors develop over time preceding cardiovascular disease (CVD).
Our objective was to examine how levels and trajectories of metabolic risk factors and bio-
chemical markers prior to diagnosis differ between people with and without CVD over a
period of up to 15–20 years. A total of 449 incident non-fatal and fatal CVD cases and 1,347
age- and sex-matched controls were identified in a prospective cohort between 1993 and
2011. Metabolic risk factors and biochemical markers were measured at five-year intervals
prior to diagnosis. Trajectories of metabolic risk factors and biochemical markers were ana-
lysed using random coefficient analyses. Although not always statistically significant, partic-
ipants with CVD had slightly more unfavourable levels for most metabolic risk factors and
biochemical markers 15–20 years before diagnosis than controls. Subsequent trajectories
until diagnosis were similar in participants with incident CVD and controls for body mass
index, diastolic blood pressure, total cholesterol, HDL cholesterol, random glucose, triglyc-
erides, gamma glutamyltransferase, C-reactive protein and uric acid. Trajectories were
more unfavourable in participants with CVD than controls for systolic blood pressure, waist
circumference and estimated glomerular filtration rate (p0.05). For example, among partic-
ipants with CVD, systolic blood pressure increased on average by 9 mmHg over the 18-
year period preceding diagnosis, whereas the increase among controls was 4 mmHg. In
conclusion, unfavourable levels of metabolic risk factors and biochemical markers are pres-
ent long before CVD, which indicates that the risk of CVD is already partly determined in
young adulthood. This underscores the need for early prevention to reduce the burden of
CVD.
PLOSONE | DOI:10.1371/journal.pone.0155978 May 20, 2016 1 / 15
a11111
OPEN ACCESS
Citation: Hulsegge G, Spijkerman AMW, van der
Schouw YT, Bakker SJL, Gansevoort RT, Smit HA, et
al. (2016) Trajectories of Metabolic Risk Factors and
Biochemical Markers prior to the Onset of
Cardiovascular Disease – The Doetinchem Cohort
Study. PLoS ONE 11(5): e0155978. doi:10.1371/
journal.pone.0155978
Editor: Pedro Tauler, University of the Balearic
Islands, SPAIN
Received: January 22, 2016
Accepted: May 6, 2016
Published: May 20, 2016
Copyright: © 2016 Hulsegge et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Due to ethical
restrictions related to participant consent, all relevant
data are available upon request to the principal
investigator of the Doetinchem Cohort Study: Dr.
WMM Verschuren (email: monique.
verschuren@rivm.nl).
Funding: This work was supported by the Ministry of
Health, Welfare and Sport of the Netherlands and the
National Institute for Public Health and the
Environment (Grant number: S/260236/01/LC), and
the Biobanking and Biomolecular Resources
Introduction
It is unclear whether cardiovascular disease (CVD) is preceded by gradual accumulation of
adverse levels of risk factors starting at young age, by relatively sudden deterioration in risk fac-
tors shortly before disease onset, or a combination of both. Although it has been well-estab-
lished that adverse levels of risk factors often develop early in life and are maintained over time
[1–6], it is not fully understood as to how they progress to CVD. For a better understanding of
the natural history of CVD, it is necessary to know how metabolic risk factors and biochemical
markers develop during the decades prior to the onset of CVD. The comparison of long-term
trajectories of metabolic risk factors and biochemical markers between those who do and those
who do not develop CVD will provide insight into the timing and the extent of pathophysiolog-
ical changes before the occurrence of CVD, which may, therefore, give an indication as to the
optimal timing of preventive actions.
Long-term trajectories of metabolic risk factors and biochemical markers preceding CVD
have hardly been explored but the few available studies suggest differences between those with
and those without CVD long before diagnosis. For example, at the age of 17, males in the Israel
Defence Forces who later developed a stenosis of more than 50% in at least one coronary artery
had similar BMI levels to the men without coronary stenosis; however, subsequent increases in
BMI up to diagnosis at the age of 25–45 years were larger in men who developed the stenosis
than among other young men.[7] In the Whitehall II study, British civil servants with CVD
had higher levels of C-reactive protein (CRP) 14 years prior to diagnosis of fatal CVD than
those individuals without CVD [8]. This difference remained similar until the occurrence of
CVD. Insight into trajectories of other important CVD risk factors, such as blood pressure [9],
lipids [10, 11], liver fat accumulation [12] and kidney function [13] may lead to a better under-
standing of the long-term physiological changes preceding CVD. Therefore, we examined how
levels and trajectories of several metabolic risk factors and biochemical markers prior to diag-
nosis among initially healthy men and women differed between those who later developed
CVD and those who did not, over a period of up to 15–20 years.
Materials and Methods
Population
The Doetinchem Cohort Study is an ongoing population-based longitudinal study of men
and women aged 20–59 years from Doetinchem, a town in the Netherlands. Men and women
were invited to undergo a clinical examination from 1987–1991 (wave 1: N = 7,768, partici-
pation rate: 62%), 1993–1997 (wave 2: N = 6,117), 1998–2002 (wave 3: N = 4,918), 2003–
2007 (wave 4: N = 4,520) and 2008–2012 (wave 5: N = 4,018). Response rates were 75% or
higher in waves 2–5. Details are described elsewhere.[14] We excluded 2,250 participants
from the current analyses based on the following exclusion criteria: participation in only one
wave (N = 1,378); missing follow up information on CVD or no informed consent for linkage
with Statistics Netherlands or the Dutch Hospital Discharge Registry (n = 416); prevalent
CVD at baseline or wave 2 based on hospital discharge data and self-reporting (N = 184);
missing data on biochemical markers in all waves due to absence of informed consent to use
blood samples for future research (N = 90); and non-participation in the wave prior to diag-
nosis of CVD (N = 182). This led to a population of 2,517 men and 3,001 women. Pregnant
women were excluded for the wave in which they were pregnant. All participants gave writ-
ten informed consent for each wave and the study was approved according to the guidelines
of the Helsinki Declaration by the Medical Ethics Committee of the University Medical Cen-
ter Utrecht.
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Measurements
Weight, height, waist circumference, diastolic and systolic blood pressure were measured and
blood samples were taken according to standard protocols [14]. Body weight was measured to
the nearest 0.1 kg on calibrated scales and 1 kg was subtracted to adjust for clothing; height was
measured to the nearest 0.5 cm. BMI was calculated as weight divided by height squared (kg/
m2). Waist circumference was measured twice to the nearest 0.5 cm, at the level midway
between the lowest rib and the iliac crest at the end of expiration, with participants in standing
position. The mean of two measurements was used for analysis. Plasma glucose levels were
determined in random non-fasting venous blood samples using the hexokinase method [15].
Diastolic and systolic blood pressure levels were measured twice after 2 minutes of rest and the
average of these two measurements was used in the analyses. Participants were measured in sit-
ting position with a random zero sphygmomanometer (Hawksley and Sons, Lancing, UK) in
waves one through three. In waves four and five a Speidel Keller meter (Welch Allyn, Skaneate-
les Falls, NY, USA) was used. Mean diastolic and systolic blood pressure levels measured dur-
ing wave four were unexpectedly higher compared to the blood pressure levels in the previous
and following waves. No clear cause could be identified, therefore, we statistically corrected
blood pressure values of wave 4, as described extensively elsewhere [16]. Total cholesterol and
HDL cholesterol were measured until 1998 in non-fasting EDTA-plasma and from 1998
onwards in serum, using standardised enzymatic methods. In 2013–2014, standardised enzy-
matic methods (Roche/Hitachi Modular P analyser, Mannheim, Germany) were used to retro-
spectively determine additional biochemical markers from waves 2–5 in non-fasting plasma
samples that had been stored at -20 degree Celsius until June 1995 and at -80 degree Celsius
from July 1995 onwards. Gamma-glutamyltransferase (GGT), uric acid, triglycerides (GPO--
PAP assay) and alanine aminotransferase (ALT) (kinetic UV assay) were measured with a col-
orimetric method. ALT measurements were excluded until June 1995 (N = 2,495) because
prior to that blood plasma was stored at -20 degree Celsius, a temperature at which ALT has
poor stability [15]. ALT (N2), and GGT (N29) values greater than three times the upper
normal reference were recoded as missing for that wave since this may indicate liver problems
[17]. High sensitivity CRP was measured with the principle of particle-enhanced immunologi-
cal agglutination (Tina-quant CRP) and cystatin C measurement was based on a particle
enhanced-turbidimetric immunoassay using reagents from Gentian (Gentian, Moss, Norway).
CRP values above 10 mg/L were recoded as missing for that wave because this may have indi-
cated an acute-phase response to infection, for example, or physical injury rather than chronic
subclinical inflammation (N80) [18]. Creatinine was measured with a Creatinine Plus assay
(IDMS traceable). Estimated glomerular filtration rate (eGFR) was estimated with the Chronic
Disease Epidemiology Collaboration (CKD-EPI) equation using a combination of cystatin C
and creatinine [19]. Data on educational attainment, smoking status and use of anti-hyperten-
sive and cholesterol-lowering medication were obtained by questionnaire.
Cardiovascular disease
Non-fatal and fatal cardiovascular events that occurred after the second examination wave
were ascertained until January 1, 2011. Cause of death was ascertained through linkage with
Statistics Netherlands, and morbidity data were obtained through probabilistic linkage with the
Dutch Hospital Discharge Registry [20]. We defined fatal CVD cases (where CVD was the pri-
mary or secondary cause of death) and non-fatal CVD cases according to ICD-9 codes 410–
414, 415.1, 427.5, 428, 430–438, 440–442, 443.9, 444, 798.1, 798.2, 798.9 [21] and correspond-
ing ICD-10 codes [22].
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Selection of controls
For each incident CVD case (N = 449), three controls were randomly selected from the same
study wave and matched on age (±3 years) and sex using incidence density sampling, which is
the preferred method for a nested case-control design and was recently also proposed for retro-
spective, longitudinal analyses [23, 24]. This led to a 1,347 controls. We matched to control as
much as possible for differences in metabolic risk factors and biochemical markers between
those with and those without CVD caused by differences in age and length of follow-up.
Data analysis
The two-sample t-test and chi-square test were used to assess differences in baseline variables
between individuals with CVD and controls.
From the date of diagnosis, participants were followed back in time for 5–24 years (Table 1),
i.e. participants diagnosed between waves 2–3, 3–4, 4–5 and after wave 5 could be followed
back in time for 6–11, 11–16, 16–21 or 21–24 years respectively. BMI, blood pressure, total
cholesterol and HDL cholesterol were followed back in time for a maximum of 24 years, and
other metabolic risk factors and biochemical markers were followed back in time for a maxi-
mum of 18 years, as those factors were not measured during the first examination wave.
Trajectories were constructed by random coefficient analyses adjusted for sex, age (linear,
plus quadratic and cubic age-terms if it statistically significantly improved model fit), examina-
tion wave and time prior to event as a linear function for each metabolic risk factor and bio-
chemical marker (dependent variable) separately. For participants with incident CVD, the
exact time of each examination prior to diagnosis was calculated by subtracting the examina-
tion date from the date of diagnosis of CVD. Matched controls were assigned the same follow-
up time as their respective cases. Age was centred at 60 years, which was approximately the
mean age at wave 5, and examination wave was centred at wave 4 to fit trajectories for a hypo-
thetical population of 60-year-olds in 2002–2007 (T0). We centred the examination wave at
wave 4 and not wave 5 for optimal power since there were only few incident CVD cases after
wave 5 (N = 38). Trajectories of diastolic and systolic blood pressure were also adjusted for
anti-hypertensive medications, and trajectories of total cholesterol, HDL cholesterol and tri-
glycerides were adjusted for cholesterol-lowering medications. We log-transformed triglycer-
ides, ALT, GGT and CRP and reported back-transformed geometric means since these
biochemical markers did not have a normal distribution.






Number of years prior to diagnosis
that measurements of BMI, DBP, SBP,
TC and HDLc were available
Number of years prior to diagnosis that
measurements of glucose, WC, TG, ALT,






120 6–11 0–5 55.4 ± 8.2
Between
waves 3–4
128 11–16 5–10 59.3 ± 8.6
Between
waves 4–5
163 16–21 10–15 64.0 ± 9.1
After wave 5 38 21–24 15–18 63.5 ± 8.8
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol;
HDLc, high-density lipoprotein cholesterol; WC, waist circumference; TG, triglycerides; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase;
CRP, C-reactive protein; UA, uric acid; eGFR, estimated glomerular ﬁltration rate
Note: For example, cases diagnosed after wave 5 had measurements of BMI, DBP, SBP, TC and HDLc for up to 21–24 years and measurements of other
risk factors and biochemical markers for up to 15–18 years prior to diagnosis. Cases diagnosed between waves 3–4 had measurements of BMI, DBP,
SBP, TC and HDLc for up to 11–16 years and measurements of other risk factors and biochemical markers for up to 5–10 years prior to diagnosis.
doi:10.1371/journal.pone.0155978.t001
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Non-linearity was investigated by fitting first-order fractional polynomials of time [25]. The
following transformations of time before event were fitted: linear, quadratic, cubic, square root,
logarithmic, and the inverse of linear, quadratic and square root. A non-linear function of time
replaced the linear function of time when the model fit was statistically significantly better
based on the likelihood ratio test (P<0.05). A second polynomial was included in the model
when inclusion further improved the model fit.
We tested differences between individuals with CVD and controls in 1) levels of metabolic
risk factors and biochemical markers 18 years before CVD, 2) subsequent trajectories until
diagnosis and 3) levels at diagnosis. Participants with incident CVD and controls were con-
trasted using the contrast statement in SAS to test differences in levels of metabolic risk factors
and biochemical markers at diagnosis and 18 years prior to diagnosis, the maximum follow-up
time of most metabolic risk factors and biochemical markers. Differences in trajectories of met-
abolic risk factors and biochemical markers between participants with incident CVD and con-
trols were statistically tested (P<0.10) using an interaction term or interaction terms for the
interaction(s) between CVD status and the time function(s) (i.e. time before event). A three-
way interaction between age, CVD status and the time function(s) tested whether differences
in trajectories between individuals with CVD and controls differed significantly by age
(P<0.10).
We had limited power to stratify the primary analyses by specific CVD endpoint (coronary
heart disease, stroke). To get an indication of potential differences in trajectories between sub-
types of CVD, we modelled trajectories of BMI, diastolic and systolic blood pressure, total cho-
lesterol and HDL cholesterol separately for coronary heart disease and stroke as a sensitivity
analysis. These were chosen because they are major risk factors of CVD, and the full follow-up
period was available for these risk factors. Trajectories were additionally adjusted for BMI and
centred at 25 kg/m2 in sensitivity analyses to investigate whether differences in trajectories
between participants with incident CVD and controls could be explained by BMI, a key driver
of the other metabolic risk factors and biochemical markers [26–29]. All analyses were per-
formed using SAS 9.3 software.
Results
In the total study population, 449 participants developed CVD (290 men; 159 women): 281
coronary heart disease events, 117 strokes and 51 other cardiovascular events occurred. For
participants with incident CVD and controls, blood pressure, total cholesterol, HDL choles-
terol and BMI (that were measured from the first wave onwards) were followed back in time
for an average of 2.9 waves and 14.9 years (range: 6.0–23.8) while the other risk factors and bio-
chemical markers (that were measured from the second wave onwards) were followed back in
time for an average of 2.2 waves and 11.1 years (range: 5.0–17.8). Participants diagnosed with
CVD later during follow-up were older (Table 1). At baseline, the average age was 45.4 (range:
20.1–59.8). Participants with incident CVD were more likely to have had a lower level of educa-
tion and to have been a smoker than controls (Table 2). At each wave, levels of the risk factors
and biochemical markers were slightly more unfavourable in participants with incident CVD
than in controls (S1 Table).
Differences in initial levels of metabolic risk factors and biochemical
markers between participants with CVD and controls
With the exception of systolic blood pressure, waist circumference, ALT and eGFR, partici-
pants with incident CVD had, on average, slightly more unfavourable levels of metabolic risk
factors and biochemical markers than controls at 18 years before diagnosis in age-adjusted
Trajectories of Risk Factors Preceding CVD
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analyses (Fig 1,Table 3 and S2 Table). This difference was only statistically significantly for
HDL cholesterol, triglycerides and random glucose (P<0.05).
Differences in trajectories of metabolic risk factors and biochemical
markers between participants with CVD and controls
The differences observed between participants with incident CVD and controls 15–20 years
before diagnosis remained stable over time for most metabolic risk factors and biochemical
markers (P0.10) (Fig 1 and Table 3). During the 18 years preceding diagnosis, in both partici-
pants with incident CVD and controls, increasing levels were seen for mean BMI (2%), dia-
stolic blood pressure (4%), random glucose (3–4%), ALT (5%), GGT (20–25%), CRP (34–64%)
and uric acid (4–6%); decreasing levels for HDL cholesterol (-3 to -4%); and stable levels for tri-
glycerides. In individuals with CVD, this resulted in statistically significantly more unfavour-
able levels of BMI, diastolic blood pressure, HDL cholesterol, triglycerides, random glucose,
GGT and uric acid at diagnosis compared to controls (P<0.01).
Levels of ALT, CRP and total cholesterol were not statistically significantly different in par-
ticipants with CVD and controls 15–20 years before diagnosis and at the end of follow-up/at
diagnosis (P0.05). Trajectories of ALT and CRP were similar in participants with CVD and
controls (P0.10), while the trajectory of total cholesterol was statistically significantly less
unfavourable in individuals with incident CVD than controls (P<0.05). The difference in
change in total cholesterol between participants with CVD and controls became 40% smaller
after adjustment for cholesterol-lowering medication but remained statistically significantly
different (P<0.05).
More unfavourable trajectories were observed in participants with CVD than in controls for
systolic blood pressure (P<0.01), waist circumference (P = 0.05) and eGFR (P<0.01) (Fig 1
and Table 3). The similar levels of these risk factors in participants with CVD and controls 15–
20 years before CVD slowly turned into more unfavourable levels in those with CVD at diagno-
sis (P<0.01). In men and women with incident CVD the mean systolic blood pressure
increased from 132 to 141 mmHg (7%) in the 18 years preceding diagnosis, while systolic
blood pressure increased from 131 to 135 mmHg (3%) in controls. During the same period,
waist circumference increased from 95 to 99 cm (4%) and eGFR decreased from 93 to 87 ml/
min/1.73m2 (-6%) in participants with incident CVD, while changes were 2–6 times smaller in
controls.
There were no statistically significant differences by age in the comparison of trajectories of
metabolic risk factors and biochemical markers between people with CVD and controls
Table 2. Baseline characteristics of participants who developed cardiovascular disease and those who did not.
Cardiovascular disease (N = 449) No cardiovascular disease (N = 1,347) P-value for difference
Demographics
Age (years), mean (SD) 45.4 (8.7) 45.5 (8.7) 0.57
Women (%) 159 (35%) 477 (35%) 1.00
Low educational level (%)* 304 (68%) 804 (60%) 0.03
Smoking status
Currently smoking (%) 198 (44%) 372 (28%) <0.01
Ex-smoker (%) 123 (27%) 475 (35%) <0.01
Medication
Anti-hypertensive medication (%) 29 (6%) 56 (4%) 0.06
Cholesterol-lowering medication (%) 0 (0%) 1 (0%) 0.30
* Intermediate secondary education or less.
doi:10.1371/journal.pone.0155978.t002
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(P0.10 for three-way interactions), with the exception of HDL cholesterol (P = 0.07 for three-
interaction) and ALT (P = 0.02 for three-way interaction).
Sensitivity analyses
Participants with coronary heart disease and stroke had no statistically significantly different
levels or trajectories of BMI, diastolic and blood pressure, total cholesterol and HDL cholesterol
during the 15–20 years prior to diagnosis (Fig 2). Other sensitivity analyses showed that adjust-
ment for BMI only slightly attenuated differences in metabolic risk factors and biochemical
markers between participants with incident CVD and controls (S1 Fig).
Discussion
Long before (up to 15–20 years prior to) the diagnosis of CVD, people with incident CVD had,
although not always statistically significant, slightly more unfavourable metabolic risk factor
Fig 1. Trajectories of bodymass index (a), DBP (b), SBP (c), total cholesterol (d), HDL cholesterol (e),
triglycerides (f), waist circumference (g), random glucose (h), ALT (i), GGT (j), C-reactive protein (k),
Uric acid (l), and eGFR (m) of those participants with incident cardiovascular disease (solid black
lines) and controls (dashed grey lines) for a hypothetical population of 60 year olds at diagnosis.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure; ALT, alanine aminotransferase;
GGT, gamma glutamyltransferase; eGFR, estimated glomerular filtration rate. The thin black lines represent
the 95% confidence intervals of mean levels of metabolic risk factors and biochemical markers for individuals
with CVD. The thin dashed grey lines represent the 95% confidence intervals of mean levels of metabolic risk
factors and biochemical markers for controls. Geometric means are shown for triglycerides, alanine
aminotransferase, gamma glutamyltransferase and C-reactive protein. An asterisk (*) indicates a statistically
significant difference in trajectory between cases and controls (P<0.10).
doi:10.1371/journal.pone.0155978.g001
Table 3. Mean levels of metabolic risk factors and biochemical markers 18 years prior to diagnosis of cardiovascular disease and at diagnosis,
and percentage change during that period, separately for cases and controls.
Mean level at T-18* Mean level at diagnosis* Percentage change between T-18 and
diagnosis
Cases Controls P-value for
difference
Cases Controls P-value for
difference
Cases Controls P-value for
difference †
Body mass index (kg/m2) 27.0 26.3 NS 27.7 26.9 <0.01 2% 2% NS
Diastolic blood pressure
(mmHg)
82 80 NS 85 83 <0.01 4% 4% NS
Systolic blood pressure
(mmHg)
132 131 NS 141 135 <0.01 7% 3% <0.01
Total cholesterol (mmol/L) 6.1 5.7 NS 6.0 5.9 NS 0% 4% <0.05
HDL cholesterol (mmol/L) 1.35 1.43 <0.05 1.30 1.42 <0.01 -3% -1% NS
Triglycerides (mmol/L) 1.5 1.4 <0.01 1.5 1.4 <0.01 0% 0% NS
Glucose (mmol/L) 5.8 5.5 <0.01 5.6 5.3 <0.05 -3% -4% NS
Waist circumference (cm) 95 95 NS 99 97 <0.01 4% 2% 0.05
ALT (U/L) 18 17 NS 19 18 NS 5% 5% NS
GGT (U/L) 22 20 NS 28 24 <0.01 25% 20% NS
C-reactive protein (mg/L) 1.3 0.9 NS 1.7 1.5 NS 34% 64% NS
Uric acid (mmol/L) 0.30 0.29 NS 0.32 0.30 <0.01 6% 4% NS
eGFR (ml/min/1.73 m2) 93 93 NS 87 92 <0.01 -6% -1% <0.01
Abbreviations: ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; eGFR, estimated glomerular ﬁltration rate; NS: not signiﬁcant.
*Age-adjusted mean levels were estimated using random coefﬁcient analyses.
†Difference in trajectory was statistically tested with interaction term(s) between time prior to diagnosis and cardiovascular disease status.
doi:10.1371/journal.pone.0155978.t003
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Fig 2. Trajectories of body mass index (a), diastolic blood pressure (b), systolic blood pressure (c), total cholesterol (d) and HDL cholesterol (e) of those
participants with incident coronary heart disease (solid black lines), incident stroke (solid grey lines) and controls (dashed grey lines) for a hypothetical
population of 60 year olds at diagnosis.
doi:10.1371/journal.pone.0155978.g002
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and biochemical marker levels than controls. Subsequent trajectories in BMI, diastolic blood
pressure, HDL cholesterol, random glucose, triglycerides, GGT, ALT, CRP and uric acid were
similar in people with incident CVD and controls until diagnosis. For systolic blood pressure,
waist circumference and eGFR, similar levels were seen at 15–20 years before diagnosis, but
more unfavourable subsequent trajectories were observed for participants with incident CVD
compared to controls.
Differences in all metabolic risk factors and biochemical markers were small in our popula-
tion but are in line with results from the INTERHEART study that also revealed small differ-
ences in mean levels of BMI (0.3 kg/m2) and HDL cholesterol (0.03 mmol/L) between
individuals with myocardial infarction and controls [30, 31]. Although we did not observe a
statistically significant difference in CRP between individuals with CVD and controls, the
mean difference in CRP (0.2-0-4 mg/L) over the 18-year period is also in accordance with find-
ings from the Whitehall II study. They showed a constant difference in mean CRP of 0.3–0.4
mg/L between people with incident fatal CVD and controls during the 14 years prior to diagno-
sis [8]. Extending the findings of the Whitehall II study to other metabolic risk factors and bio-
chemical markers, our results suggest that differences in most other metabolic risk factors and
biochemical markers were already present long before diagnosis, and, in general, subsequent
trajectories were similar between individuals with CVD and controls up to the occurrence of
CVD. These differences were not explained by differences in BMI, and, in general, did not dif-
fer by age at diagnosis. These findings underscore the fact that CVD is caused by a long-term
multifactorial disease process in which adverse effects of elevated levels of multiple risk factors
are already present at young age and slowly accumulate over time, rather than being the result
of rapidly increasing levels of risk factors in the years preceding diagnosis.
We observed a larger increase in total cholesterol in controls than in participants with CVD.
This may be the result of a larger increase in the use of statins in individuals with CVD than
controls. Indeed, in participants with CVD use of cholesterol-lowering medication was 50%
higher than in controls. Although additional adjustment for cholesterol-lowering medication
attenuated the difference in trajectory of total cholesterol between cases and controls by 40%, it
may not fully account for this increase in statin use.
During the 15–20 years preceding CVD, the course of only two of the metabolic risk factors
and one of the biochemical markers was different in individuals with incident CVD than in
controls: increases in systolic blood pressure, waist circumference and eGFR were larger in par-
ticipants with incident CVD than in controls. This suggests that unfavourable changes in these
three risk factors in the 15–20 years prior to diagnosis might be important in the development
of CVD. Independently from BMI, waist circumference is associated with systolic blood pres-
sure and GFR [32, 33], which suggests that the unfavourable trajectory in waist circumference
partially drives the unfavourable trajectories of blood pressure and eGFR. Blood pressure and
GFR are also highly related, and each may adversely affect the other [34, 35]. The trajectory of
eGFR may, therefore, resemble the trajectory of systolic blood pressure, and vice versa. In addi-
tion, unfavourable changes in either GFR or systolic blood pressure may also exacerbate the
effect of the other. Although the unfavourable trajectories of systolic blood pressure, waist cir-
cumference and eGFR in people with incident CVD are biological plausible, the possibility of
chance findings cannot be ruled out.
The more unfavourable trajectory in waist circumference but not in BMI in participants
with incident CVD in comparison to controls suggests that unfavourable changes in intra-
abdominal adiposity may be more important in the development of CVD than changes in gen-
eral adiposity. The INTERHEART study also observed a stronger relationship for waist cir-
cumference and myocardial infarction than with BMI [36]. This is compatible with the fact
that adipose tissue produces and secretes many bioactive molecules such as leptin, adiponectin,
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angiotensinogen, and inflammatory molecules. These adipokines also interact with other tis-
sues and cells in the body that are linked with CVD [37]. In addition, the more rapid increase
in waist circumference, and thus in abdominal fat, in individuals with CVD than in controls,
while changes in BMI (a measure of general adiposity) were similar, is consistent with a change
in fat distribution in the 10–15 years preceding CVD. If such a change in fat distribution would
be accompanied by an overall increase in fat mass, the fact that changes in BMI are similar
would likely imply that overall increases in fat mass are accompanied by decreases in muscle
mass. This is in line with our secondary analyses, in which we found that, in people with CVD,
the decline in eGFR based on cystatin C (-7.3 ml/min/1.73m2) was larger than the decline in
eGFR based on creatinine (-3.0 ml/min/1.73m2) during the 20 years prior to diagnosis (data
not shown). Creatinine might remain higher due to a decline in muscle mass, while cystatin C
better demonstrates the true decline in kidney function [38, 39].
The presence of unfavourable risk factor levels 15–20 years or more prior to CVD, the fact
that CVD event rates increase progressively after the age of 45 years [40–42], and, of course, given
that we want to prevent or postpone as many of those cases as possible, underscore the need for
CVD prevention in young adulthood. Small elevations in metabolic risk factors and biochemical
markers are often not considered clinically relevant at a young age, but our findings indicate that
small elevations in most metabolic risk factors and biochemical markers remain the same–they
do not disappear–during the 15–20 years preceding CVD. These findings suggests that unfavour-
able levels are already harmful at a young age, and, they emphasize the importance of maintaining
favourable levels of general adiposity, blood pressure, lipids, markers of liver fat, chronic inflam-
mation and kidney function from young adulthood onwards by way of a healthy lifestyle, includ-
ing a healthy diet and physical activity. Preventing deterioration of systolic blood pressure,
abdominal adiposity and kidney function in young adulthood andmiddle age might be especially
warranted since these factors deteriorated more rapidly in people with CVD than controls until
diagnosis. In addition, when extrapolating our findings to CVD risk prediction, the relatively
small differences in mean levels of metabolic risk factors and biochemical markers between peo-
ple with CVD and controls underscores the difficulty in differentiating between those who will
and those who will not develop CVD long before diagnosis [43]. The similar long-term course of
the majority of risk factors in people with CVD and controls also suggests that it is unlikely that
multiple measurements of risk factors can improve the performance of CVD prediction models.
Our approach using the modelling of long-term trajectories preceding CVD yields impor-
tant insights into physiological changes preceding CVD. The strengths of this study are that
the same group of trained study personnel objectively measured various metabolic risk factors
and biochemical markers in a population-based cohort over a long period. Our study has also
certain limitations, in that relatively few participants had measurements of metabolic risk fac-
tors and biochemical markers over the full follow-up period due to the limited incidence of
CVD after wave 5 (N = 38), which led to relatively large 95% confidence intervals at 20 years or
more before diagnosis. Although all types of CVD share common risk factors, the strength of
risk factors differs by endpoint. For example, hypertension is more strongly associated with
stroke than with coronary heart disease [44, 45]. In sensitivity analyses, we observed only small
statistically insignificant differences in levels and trajectories between people with stroke and
coronary heart disease. Combining all subtypes of CVD has, therefore, probably led to a small
underestimation of the differences in metabolic risk factors and biochemical markers between
cases and controls. Furthermore, the non-responders and the excluded participants had slightly
more unfavourable levels of the metabolic risk factors and biochemical markers than the study
participants. This may have led to an underestimation of the proportion of adults with incident
CVD and, as a consequence may have slightly underestimated differences in levels of metabolic
risk factors and biochemical markers between people with incident CVD and controls.
Trajectories of Risk Factors Preceding CVD
PLOSONE | DOI:10.1371/journal.pone.0155978 May 20, 2016 11 / 15
Conclusions
The present study suggests that people with incident CVD have more unfavourable levels, but
a similar course, of most metabolic risk factors and biochemical markers compared to controls
during the 15–20 years preceding CVD. In contrast, the course of systolic blood pressure, waist
circumference and kidney function was more unfavourable in people with CVD than in con-
trols, leading to increasing differences during the 15–20 years preceding diagnosis. These find-
ings seem to indicate that the risk of CVD is already partly determined in young adulthood;
thereby stressing the need for primary prevention measures targeted at all risk factors, such as
encouraging physical activity and a healthy diet in individuals starting from childhood/young
adulthood onwards.
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